FDA Grants Priority Review to Melflufen for Myeloma
The FDA has granted priority review to a New Drug application for INN melphalan flufenamide, or melfufen, in combination with dexamethasone for the treatment...
Phase I Trial Supports CC-92480 for Heavily Pretreated Myeloma
Results from a first-in-human trial of CC-92480 in patients with relapsed or refractory multiple myeloma show a manageable safety profile and promising efficacy, according...
FDA Approves Belantamab Mafodotin-blmf for Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin-blmf, an anti–B-cell maturation antigen (BCMA) antibody-drug conjugate therapy, received accelerated approval for the treatment of adults with relapsed or refractory multiple myeloma...
Isatuximab Plus Carfilzomib: A New Standard for Relapsed/Refractory Myeloma?
The three-drug combination of the CD38-targeting antibody isatuximab plus carfilzomib and dexamethasone significantly improved progression-free survival (PFS) in patients with relapsed or refractory multiple...
Idecabtagene Vicleucel Demonstrates Deep, Durable Responses in Relapsed/Refractory Myeloma
The BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (previously known as bb2121) induced responses in nearly three-quarters of patients with relapsed/refractory multiple...
DREAMM-6: Evaluating Belantamab Mafodotin and Bortezomib Plus Dexamethasone in Relapsed/Refractory Myeloma
Early data from the DREAMM-6 study suggest that the combination of belantamab mafodotin, bortezomib, and dexamethasone is active in patients with relapsed or refractory...
Study Supports Use of AHCT Over VMP as Intensification in Newly Diagnosed Myeloma
In patients with newly diagnosed myeloma, following induction chemotherapy, early autologous hematopoietic cell transplantation (AHCT) as intensification therapy prolonged progression-free survival (PFS), compared with...
BCMA Bispecific Antibody “Promising” for Relapsed or Refractory Myeloma
Interim results from a phase I dose-finding study suggest that CC-93269, a bispecific antibody that binds B-cell maturation antigen (BCMA) on malignant plasma cells...
Pomalidomide-Based Regimen Associated With Durable Response in Lenalidomide-Refractory Myeloma
Treatment with a regimen consisting of pomalidomide, low-dose dexamethasone, and daratumumab as either second- or third-line therapy induced durable responses in a high proportion...
Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma
The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple myeloma (MM). Daratumumab was...
Current Issue
September 2020 Volume 6, Issue 11
This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.